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https://doi.org/10.1016/j.jaci.2017.12.995Incidence and sociodemographic
characteristics of eczema diagnosis
in children: A cohort studyTo the Editor:
We report the results of a large population-based cohort
study examining the incidence of clinically diagnosed
eczema in children and the variations by sociodemographic
characteristics. Eczema (also known as atopic eczema/
dermatitis1) affects up to 1 in 5 children2 and is associated
with high morbidity.3
There are limited estimates on the incidence of eczema and
how the incidence varies by sociodemographic factors, which is
important for generating hypotheses regarding the disease
etiology and for health service planning. To address this issue,
we examined the incidence of eczema diagnosis in children aged
0 to 17 years between April 1, 1997, and March 31, 2015, using
the Clinical Practice Research Datalink (CPRD).4 CPRD is a
routinely collected primary care database in the United Kingdom
covering approximately 7% of the UK population.4 CPRD has
been linked to the Hospital Episode Statistics, a secondary health
care administrative database in England, and is broadly
representative of the general UK population regarding age, sex,
and lifestyle-related factors.4,5
We defined a child as having eczema if he or she had 1
diagnostic code for eczema with at least 2 eczema-related
treatment codes on separate days within 3 months before or
1 year after the eczema diagnosis (for additional details, see this
article’s Online Repository at www.jacionline.org). The earliest
date of an eczema diagnosis was defined as the incidence date.
Previous research6 has shown that the combination of 1 eczema
diagnostic code with 2 eczema-related treatment codes on
separate days at any time gives a 90% (95% CI, 83%-96%)
positive predictive value for identifying prevalent eczema in
children. We excluded children registered with their current
primary care practice after 3 months of birth or children with a
history of eczema before the start of the study to minimize the
risk of misclassifying recurrent eczema events as first events
(for additional details, see Fig E1 in this article’s Online
Repository at www.jacionline.org). 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).We calculated incidence rates per 100 person-years and
adjusted rate ratios (aRRs) for age (<1 year old, 1-4 years old,
5-17 years old), sex, socioeconomic status (defined as quintiles
of the patient-level English Index of Multiple Deprivation7),
and ethnicity (when available) using Poisson regression
modeling with mutual adjustment (see Table I). Because people
with different sociodemographic characteristics could have
different health-seeking behaviors, we also adjusted for the
number of annual consultations in the study follow-up period
to minimize potential ascertainment bias. We also examined
the incidence rate and aRR for calendar year adjusted for age,
sex, and socioeconomic status. We examined whether there
was evidence of statistical interaction between age and sex,
socioeconomic status, and ethnicity using the likelihood ratio
test (P < .05). Because the quality of ethnicity recording in
the Hospital Episode Statistics–linked CPRD population is
only comparable to the UK population for people registered
after 2006,8 for any analysis using ethnicity data we excluded
children registered before April 1, 2006, and conducted a
complete case analysis. To test the robustness of our results,
we conducted 4 sensitivity analyses (see this article’s Online
Repository at www.jacionline.org). The study protocol was
approved by the Independent Scientific Advisory Committee
(Protocol No: 16_056) and published here: https://www.cprd.
com/isac/Protocol_16_056.asp.
The study population consisted of 675,087 children of which
98,082 (14.5%) had a first clinical diagnosis of eczema.
Compared with children without eczema, children with eczema
had a slightly longer follow-up period and a higher annual
consultation rate (see Table E1 in this article’s Online Repository
at www.jacionline.org).
The incidence rate by calendar year remained stable in the
period 1997 to 2015 (see Fig E2 in this article’s Online
Repository at www.jacionline.org) and the aRR for each
additional calendar year was 1.0 (95% CI, 1.0-1.0). The
incidence rate of eczema was highest in the first year of life
(13.8 per 100 person-years; 95% CI, 13.7-13.9) and decreased
substantially afterward (Fig 1). We found statistically
significant interaction between age and other sociodemo-
graphic factors (P < .001). There was a 30% higher incidence
rate in boys than in girls in children younger than 1 year
(aRR, 1.3; 95% CI, 1.3-1.4) and a 20% lower rate in boys
than in girls for children 5 years or older (aRR, 0.8; 95% CI,
0.7-0.8) (Table I). On comparing the incidence rate in children
of the lowest socioeconomic status with that in children of the
highest socioeconomic status, we found that the latter had a
20% higher incidence rate in the younger age groups (aRR,
1.2; 95% CI, 1.2-1.3 in <1-year-olds; aRR, 1.2; 95% CI,
1.1-1.3 in 1-4-year-olds); such difference however was not
observed in children 5 years or older (Table I). Moreover, the
incidence of clinically diagnosed eczema in the first year of
life was 2- to 3-fold higher in Chinese children (aRR, 3.4;
95% CI, 3.0-3.8), Bangladeshi children (aRR, 2.5; 95% CI,
2.3-2.8), and Black Caribbean children (aRR, 2.5; 95% CI,
2.3-2.9) compared with white children (Table I). The incidence
decreased by age for all ethnic groups but generally remained
higher in nonwhite children than in white children (see Table
E2 in this article’s Online Repository at www.jacionline.org).
Results from the sensitivity analyses were all similar compared
with the main analysis (see Tables E3-E5 in this article’s Online
Repository at www.jacionline.org).
TABLE I. Incidence rates and rate ratios of eczema by different sociodemographic factors stratified by age (N 5 675,087)
Sociodemographic factor
<1-y-olds (n of eczema 5 55,525) 1-4-y-olds (n of eczema 5 34,729) 5-17-y-olds (n of eczema 5 7,828)
Rate* (95% CI) aRRy (95% CI) Rate* (95% CI) aRRy (95% CI) Rate* (95% CI) aRRy (95% CI)
Sex
Male 15.9 (15.7-16.1) 1.3 (1.3-1.4) 2.9 (2.9-3.0) 0.9 (0.9-1.0) 0.4 (0.3-0.4) 0.8 (0.7-0.8)
Female 11.7 (11.5-11.8) Reference 3.0 (2.9-3.0) Reference 0.5 (0.5-0.5) Reference
Index of Multiple Deprivation
1 (least deprived) 15.5 (15.3-15.8) 1.2 (1.2-1.3) 3.2 (3.2-3.3) 1.2 (1.1-1.3) 0.4 (0.4-0.4) 1.0 (0.9-1.1)
2 13.7 (13.5-14.0) 1.1 (1.0-1.1) 3.0 (2.9-3.1) 1.1 (1.0-1.1) 0.4 (0.4-0.4) 1.0 (0.9-1.1)
3 13.5 (13.3-13.8) 1.0 (1.0-1.1) 2.9 (2.8-3.0) 1.0 (0.9-1.1) 0.4 (0.4-0.4) 1.0 (0.9-1.1)
4 13.1 (12.8-13.3) 1.0 (1.0-1.1) 2.8 (2.8-2.9) 1.0 (0.9-1.1) 0.4 (0.4-0.5) 1.0 (1.0-1.1)
5 (most deprived) 12.9 (12.6-13.2) Reference 2.8 (2.7-2.9) Reference 0.4 (0.4-0.5) Reference
Ethnicity§ n of eczema 5 25,593 n of eczema 5 12,862 n of eczema 5 391
White 12.4 (12.2-12.6) Reference 3.3 (3.2-3.3) Reference 0.5 (0.4-0.5) Reference
Black Caribbean 28.8 (25.6-32.4) 2.5 (2.3-2.9) 5.4 (4.5-6.6) 2.0 (1.6-2.4) 1.5 (0.6-4.0) 3.5 (1.3-9.3)
Bangladeshi 30.4 (27.2-34.1) 2.5 (2.3-2.8) 5.3 (4.3-6.5) 1.4 (1.1-1.7) 1.0 (0.3-3.0) 1.6 (0.5-5.1)
Chinese 41.7 (36.9-47.2) 3.4 (3.0-3.8) 4.6 (3.4-6.2) 1.6 (1.2-2.2) 0.7 (0.1-5.1) 1.9 (0.3-13.3)
All other ethnic groups combinedk 20.8 (20.2-21.4) 1.7 (1.6-1.8) 3.9 (3.8-4.1) 1.1 (1.0-1.2) 1.0 (0.8-1.2) 1.9 (1.5-2.5)
*Rate per 100 person-years.
For sex, model adjusted for Index of Multiple Deprivation and the number of annual consultations during the study follow-up period; for Index of Multiple Deprivation, model
adjusted for sex and the number of annual consultations during the study follow-up period; for ethnicity (available only for children registered after 2006), model adjusted for sex,
Index of Multiple Deprivation, and the number of annual consultations during the study follow-up period.
P < .05.
§Restricted to children with current registration dates on or after April 1, 2006 (N 5 303,327 of which 48,301 with eczema), and a complete case analysis was conducted first by
excluding 55,529 (18.3%) children with missing ethnicity data (N 5 247,798).
kIncluding mixed, black African, black other, Indian, Pakistani, Asian other, and other children (eg, Egyptian).
FIG 1. Incidence rate (per 100 person-years) of eczema by age and sex, N 5 675,087 (dotted lines showing
95% CI).
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by age and is highest in the first year of life, especially in boys,
Chinese, Bangladeshi, and Black Caribbean children, and children
of high socioeconomic status. The study confirms the previously
reported link between high socioeconomic status and the
occurrence of eczema,9 and also reports novel findings on ethnic
group and sex differences. The former could be due to differentenvironmental risk factors such as diet, living conditions at home,
or decreased exposure to ultraviolet light.E1-E3 The latter may be
potentially due to different immune responses of boys and girls in
early childhood,E4 but different environment exposures such as
differing exposures to soap/shampoo productsE5 at older age.
The main strength of our study is the large sample size, which
has allowed us to examine interactions with age. A potential
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LETTERS TO THE EDITOR 1929limitation is ascertainment bias, but we have tried to minimize
this by adjusting for the number of annual consultations during
the study follow-up period in all the analyses.
In conclusion, our findings highlight the early onset of eczema
in children, with higher incidence found in boys, Chinese,
Bangladeshi, and Black Caribbean children, and those with
high socioeconomic status. With new prevention approaches
potentially availableE6 and early intervention trials currently
underway,E7 our study may help policymakers identify
high-risk children and better allocate limited health care
resources.
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https://doi.org/10.1016/j.jaci.2017.12.997Group 2 innate lymphoid cells promote
airway hyperresponsiveness through
production of VEGFATo the Editor:
Asthma is a complex and heterogeneous disease characterized
by chronic airway inflammation, airway hyperresponsiveness
(AHR), and airway remodeling. We recently demonstrated the
importance of group 2 innate lymphoid cells (ILC2s) in AHR.1
Their precise roles in asthma, and the specific effector
mechanisms through which ILC2s would promote AHR, remain
unclear. Recent work indicates that ILC2s may have important
functions other than producing classical T helper cytokines. By
reanalyzing previously published microarray data,2 we found
that VEGFAwas one of the highest expressed genes in activated
ILC2.
Vascular endothelial growth factor A (VEGFA) (formerly
VEGF) is a protein member of the platelet-derived growth
factor/VEGF family. VEGFA was shown to induce eosinophilic
airway inflammation, mucus metaplasia, subepithelial fibrosis,
myocyte hyperplasia, dendritic cell activation, and to elicit AHR
through IL-13-dependent and -independent mechanisms.3
To investigate the relevance of VEGFA expression in human
ILC2s, we isolated ILC2s from the blood of healthy controls
and patients with asthma and examined mRNA expression of
Vegfa together with other VEGF family members (see Table E1 in
this article’s Online Repository at www.jacionline.org). Human
ILC2 were identified as CD451Lin⁻IL-7Ra1CRTH21 cells
(Lin 5 lineage; see Fig E1 in this article’s Online Repository at
www.jacionline.org). ILC2s in healthy controls expressed very
low or undetectable levels of Vegfa mRNA (Fig 1, A). However,
Vegfa mRNA expression in ILC2 of patients with asthma
was significantly increased (P < .05, Mann-Whitney U test)
(Fig 1, A). Vegfb and Vegfc mRNA was also detected in human
ILC2s, but the expression levels of these 2 molecules were
comparable between ILC2s from healthy controls and those
from patients with asthma (Fig 1, A). Vegfd and Pgf mRNAwas
undetectable in human ILC2s from either healthy controls or
patients with asthma. Together, these data indicated that Vegfa
mRNA expression in ILC2s is selectively upregulated in human
asthma. To study whether such differences in gene activation
were associated with differential VEGFA protein expression,
we sorted human ILC2s and cultured them with IL-25, IL-33,
and IL-2. ILC2s from both healthy controls and patients
with asthma were capable of producing VEGFA protein in vitro
(Fig 1, B). However, ILC2s from patients with asthma produced
higher amounts of VEGFA in response to activating cytokines
(Fig 1, B). Of note, ILC2s cultured without cytokines failed to
produce VEGFA, verifying that production of VEGFA is a
signature of ILC2 activation (Fig E1).
To examine the in vivo relevance of ILC2 activation, we treated
mice with IL-33. Mouse lung ILC2s were identified as
CD451Lin⁻Thy11ST21 cells (see Fig E2 in this article’s Online
Repository at www.jacionline.org). mRNA expression of Il5
METHODS
Defining eczema
Diagnoses in the CPRD are coded using the Read code system, which is
based on a hierarchal clinical classification system and can be cross referenced
to the International Classification of Disease.E8 We defined a child as having
eczema if he or she had 1 diagnostic code for eczema (Read codes M111.00
Atopic dermatitis/eczema, M112.00 Infantile eczema, M113.00 Flexural
eczema, M114.00 Allergic intrinsic eczema, M12z100 Eczema NOS) with
at least 2 eczema-related treatment codes on separate days within 3 months
before or 1 year after the diagnosis. The following eczema-related treatments
were used: prescriptions of emollients, topical steroids, topical calcineurin
inhibitors (including pimecrolimus and tacrolimus), systemic steroids,
systemic immunomodulatory agents (including methotrexate, cyclosporine,
azathioprine, and mycophenolate mofetil), and ultraviolet light therapy.
Drug prescriptions were identified from the CPRD using drug codes based
on the British National Formulary chapters. Ultraviolet light therapy
treatments were identified from both the CPRD and Hospital Episode
Statistics using Read and OPCS4 codes, respectively.
Sensitivity analyses
To test the robustness of our results, we conducted 4 sensitivity analyses
and compared the results to the main analysis.
1. Missing ethnicity data: Because 18.3% children had missing information
on ethnicity, we used multiple imputation to replace missing values for
ethnicity by using multinomial logistic regression and created 10 imputed
data sets. We combined estimates using Rubin’s rule to obtain final
estimates and compared the results to the complete case analysis.
2. More inclusive eczema definition: We defined a child as having eczema if
he or she had 1 diagnostic code for eczema with at least 1 eczema-related
treatment within 3 months before or after the eczema diagnosis.
3. More restrictive eczema definition for the first year of life: To minimize
the potential misclassification of eczema diagnosis in the first year of
life, we defined a child as having eczema in the first year if he or she
had eczema in the first year and prescribed any eczema-related treatment
in the second year of life also.
4. Alternative study population: Because we excluded a large proportion of
children, that is, those registered with their current primary care physician
after the first 3 months of birth (1,097,638 out of 1,838,877; 59.7%), our
study population could be less representative of the general pediatric
population. Therefore, we re-ran our analysis on the total population
identified from the Hospital Episode Statistics–linked CPRD. For this
sensitivity analysis, to ensure we included only incident diagnoses and
not prevalent ones in children registered after the first year of life, we
excluded the first 12 months after the current registration date and
children whose first eczema diagnosis was within this first 12 months
period were also excluded.
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Children aged 0-17 years between April 1997 and 
March 2015 from HES linked CPRD (N=1,838,877)
Children registered with current general practice within 
3 months after birth (N=731,239)
Final study population (N=675,087)
The following types of children with a history of 
eczema before the start of the follow-up period were 
excluded:
At least one of the five Read codes for eczema 
before the start of follow-up (n=45,938)
Eczema inpatient diagnosis as first recording of 
eczema (n=656)
Eczema history code (i.e. H/O: eczema) as 
first recording of eczema (n=7,569)
Children without eczema at the start of the follow-up period 
(N=677,076)
Children with missing information on socioeconomic 
status were excluded (n=1,989)
FIG E1. Constructing the final study population (N 5 675,087). H/O, History of; HES, Hospital Episode
Statistics.
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FIG E2. Incidence rate (per 100 person-years) of eczema by calendar year, N 5 675,087.
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TABLE E1. Characteristic of children without and with eczema (N 5 675,087)
Characteristic Children without eczema (n 5 577,005) Children with eczema (n 5 98,082)
Age at registration with current GP (mo), median (IQR) 0.77 (0.20-1.40) 0.80 (0.37-1.33)
Age at start of prospective follow-up (mo), median (IQR) 1.30 (0.63-16.67) 0.90 (0.47-1.57)
Average length of prospective follow-up (mo), median (IQR) 54.73 (20.22-112.00) 74.27 (37.53-125.93)
Sex, male 293,828 (50.92) 53,124 (54.16)*
Index of Multiple Deprivation
1 (least deprived) 123,060 (21.33) 24,334 (24.81)*
2 120,913 (20.96) 20,646 (21.05)
3 110,121 (19.08) 18,019 (18.37)
4 117,033 (20.28) 18,442 (18.80)
5 (most deprived) 105,878 (18.35) 16,641 (16.97)
Ethnicity n 5 255,026 n 5 48,301
White 176,964 (84.69) 30,761 (79.19)*
Mixed 7,824 (3.74) 1,604 (4.13)
Black Caribbean 1,094 (0.52) 378 (0.97)
Black African 4,779 (2.29) 1,172 (3.02)
Black other 1,030 (0.49) 323 (0.83)
Indian 4,560 (2.18) 1,319 (3.40)
Bangladeshi 1,084 (0.52) 396 (1.02)
Pakistani 4,265 (2.04) 1,114 (2.87)
Chinese 704 (0.34) 294 (0.76)
Asian other 2,961 (1.42) 790 (2.03)
Other 3,687 (1.76) 695 (1.79)
Missing 46,074 9,455
Annual consultation rate, median (IQR) 3.50 (1.84-6.36) 10.29 (5.92-16.23)*
Values are n (%) unless otherwise indicated.
GP, General practitioner; IQR, interquartile range.
*P < .05.
Restricted to children with current registration dates on or after April 1, 2006 (N 5 303,327 of which 48,301 with eczema), and a complete case analysis was conducted first by
excluding 55,529 (18.3%) children with missing ethnicity (N 5 247,798).
Number of consultations per year during the study follow-up period.
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TABLE E2. Incidence rates and rate ratios of eczema by ethnicity stratified by age (N 5 247,798 with complete data on ethnicity)
Ethnicity
<1-y-olds (n of eczema 5 25,593) 1-4-y-olds (n of eczema 5 12,862) 5-17-y-olds (n of eczema 5 391)
Rate* (95% CI) aRRy (95% CI) Rate* (95% CI) aRRy (95% CI) Rate* (95% CI) aRRy (95% CI)
White 12.4 (12.2-12.6) Reference 3.3 (3.2-3.3) Reference 0.5 (0.4-0.5) Reference
Mixed 17.7 (16.7-18.8) 1.5 (1.4-1.6) 3.7 (3.3-4.0) 1.1 (1.0-1.3) 0.6 (0.3-1.0) 1.2 (0.7-2.3)
Black Caribbean 28.8 (25.6-32.4) 2.6 (2.3-2.9) 5.4 (4.5-6.6) 2.0 (1.6-2.4) 1.5 (0.6-4.0) 3.5 (1.3-9.4)
Black African 22.3 (20.8-23.8) 2.0 (1.8-2.1) 3.9 (3.5-4.4) 1.3 (1.2-1.5) 1.1 (0.6-1.9) 2.6 (1.5-4.5)
Black other 29.6 (26.1-33.5) 2.6 (2.3-3.0) 4.0 (3.1-5.1) 1.4 (1.1-1.8) 2.4 (1.2-4.8) 5.8 (2.8-11.8)
Indian 24.3 (22.9-25.9) 1.8 (1.6-2.0) 4.2 (3.7-4.6) 1.2 (1.1-1.4) 0.9 (0.6-1.6) 1.8 (1.1-3.1)
Bangladeshi 30.4 (27.2-34.1) 2.5 (2.3-2.8) 5.3 (4.3-6.5) 1.4 (1.1-1.7) 1.0 (0.3-3.0) 1.6 (0.5-5.1)
Pakistani 20.6 (19.2-22.1) 1.7 (1.5-1.9) 4.1 (3.7-4.6) 0.7 (0.5-1.2) 0.8 (0.5-1.4) 1.4 (0.8-2.5)
Chinese 41.7 (36.9-47.2) 3.4 (3.0-3.8) 4.6 (3.4-6.2) 1.6 (1.2-2.2) 0.7 (0.1-5.1) 1.9 (0.3-13.3)
Asian other 23.6 (21.8-25.6) 2.0 (1.8-2.1) 4.4 (3.8-5.1) 1.2 (1.1-1.4) 1.8 (1.0-3.3) 3.3 (1.8-6.1)
Other (eg, Egyptian) 16.4 (15.0-17.9) 1.3 (1.1-1.5) 3.6 (3.1-4.2) 1.2 (1.0-1.4) 0.7 (0.3-1.8) 1.6 (0.6-3.8)
*Rate per 100 person-years.
Model adjusted for sex, Index of Multiple Deprivation, and the number of annual consultations during the study follow-up period.
Compared with Table I, these estimates changed slightly because of a different number of covariates included in the regression model.
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TABLE E3. Results after using a more inclusive eczema definition: Incidence rates and rate ratios of eczema by sociodemographic
factors stratified by age (N 5 675,087 for analysis on sex and Index of Multiple Deprivation and N 5 247,798 for analysis on ethnicity)
Characteristic
<1-y-olds (n of eczema 5 70,425) 1-4-y-olds (n of eczema 5 57,809) 5-17-y-olds (n of eczema 5 18,247)
Rate* (95% CI) aRRy (95% CI) Rate* (95% CI) aRRy (95% CI) Rate* (95% CI) aRRy (95% CI)
Sex
Male 20.3 (20.1-20.5) 1.3 (1.3-1.3) 5.3 (5.2-5.3) 1.0 (0.9-1.0) 0.9 (0.9-0.9) 0.7 (0.7-0.8)
Female 15.3 (15.1-15.5) Reference 5.4 (5.4-5.4) Reference 1.2 (1.2-1.3) Reference
Index of Multiple Deprivation
1 (least deprived) 20.0 (19.7-20.3) 1.2 (1.2-1.2) 5.9 (5.8-6.0) 1.1 (1.1-1.2) 1.1 (1.1-1.1) 1.0 (1.0-1.1)
2 17.8 (17.5-18.1) 1.1 (1.1-1.1) 5.4 (5.3-5.5) 1.1 (1.1-1.1) 1.1 (1.0-1.1) 1.0 (1.0-1.1)
3 17.5 (17.2-17.8) 1.1 (1.0-1.1) 5.2 (5.1-5.3) 1.1 (1.0-1.1) 1.1 (1.0-1.1) 1.0 (1.0-1.1)
4 16.9 (16.6-17.2) 1.0 (1.0-1.1) 5.0 (4.9-5.1) 1.0 (1.0-1.1) 1.0 (1.0-1.1) 1.0 (0.9-1.0)
5 (most deprived) 16.5 (16.2-16.8) Reference 4.9 (4.8-5.0) Reference 1.1 (1.0-1.1) Reference
Ethnicity n of eczema 5 32,215 n of eczema 5 20,476 n of eczema 5 893
White 16.2 (16.0-16.4) Reference 5.7 (5.6-5.8) Reference 1.3 (1.2-1.3) Reference
Mixed 22.1 (21.0-23.3) 1.4 (1.3-1.5) 6.0 (5.6-6.5) 1.1 (1.0-1.2) 1.5 (1.0-2.2) 1.2 (0.8-1.8)
Black Caribbean 33.6 (30.1-37.5) 2.3 (2.0-2.5) 7.1 (6.0-8.5) 1.3 (1.1-1.6) 2.4 (1.1-5.3) 2.0 (0.9-4.6)
Black African 26.2 (24.6-27.9) 1.8 (1.7-1.9) 5.5 (5.0-6.1) 1.0 (0.9-1.1) 1.8 (1.2-2.8) 1.4 (0.9-2.3)
Black other 33.1 (29.5-37.3) 2.2 (2.0-2.5) 5.7 (4.6-7.0) 1.1 (0.9-1.3) 3.9 (2.2-6.9) 3.5 (2.0-6.3)
Indian 28.8 (27.1-30.5) 1.7 (1.5-1.8) 6.4 (5.9-7.0) 1.1 (1.0-1.2) 1.5 (1.0-2.4) 1.1 (0.7-1.8)
Bangladeshi 34.1 (30.6-38.0) 2.2 (1.9-2.4) 7.8 (6.5-9.2) 1.3 (1.1-1.6) 3.4 (1.7-6.4) 2.3 (1.2-4.5)
Pakistani 23.5 (22.0-25.1) 1.5 (1.4-1.6) 5.9 (5.4-6.5) 1.0 (0.9-1.1) 1.8 (1.2-2.7) 1.3 (0.9-2.0)
Chinese 51.0 (45.5-57.1) 3.1 (2.8-3.5) 7.6 (5.9-9.7) 1.4 (1.1-1.8) 0.8 (0.1-6.0) 0.8 (0.1-5.5)
Asian other 28.0 (26.0-30.2) 1.8 (1.6-1.9) 6.2 (5.5-7.1) 1.1 (1.0-1.2) 2.5 (1.5-4.2) 1.9 (1.1-3.2)
Other 21.2 (19.6-22.9) 1.3 (1.1-1.4) 5.7 (5.1-6.4) 1.0 (0.9-1.2) 1.8 (1.0-3.2) 1.5 (0.8-2.6)
*Rate per 100 person-years.
Model adjusted for sex, Index of Multiple Deprivation, and the number of annual consultations during the study follow-up period.
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TABLE E4. Results after using a more strict eczema definition for the first year of life: Incidence rates and rate ratios of eczema by
sociodemographic factors stratified by age (N 5 675,087 for analysis on sex and Index of Multiple Deprivation and N 5 247,798 for
analysis on ethnicity)
Characteristic
<1-y-olds (n of eczema 5 39,579) 1-4-y-olds (n of eczema 5 34,729) 5-17-y-olds (n of eczema 5 7,828)
Rate* (95% CI) aRRy (95% CI) Rate* (95% CI) aRRy (95% CI) Rate* (95% CI) aRRy (95% CI)
Sex
Male 11.0 (10.9-11.2) 1.3 (1.3-1.3) 2.9 (2.8-2.9) 1.0 (0.9-1.0) 0.4 (0.3-0.4) 0.7 (0.7-0.9)
Female 8.2 (8.1-8.3) Reference 2.9 (2.9-3.0) Reference 0.5 (0.5-0.5) Reference
Index of Multiple Deprivation
1 (least deprived) 11.2 (11.0-11.4) 1.3 (1.2-1.4) 3.1 (3.1-3.2) 1.2 (1.1-1.2) 0.4 (0.4-0.4) 0.9 (0.9-1.0)
2 9.7 (9.5-9.9) 1.1 (1.1-1.2) 2.9 (2.9-3.0) 1.1 (1.0-1.1) 0.4 (0.4-0.4) 0.9 (0.9-1.0)
3 9.4 (9.2-9.6) 1.0 (0.9-1.1) 2.8 (2.7-2.9) 1.0 (1.0-1.0) 0.4 (0.4-0.4) 0.9 (0.9-1.0)
4 8.9 (8.7-9.1) 1.1 (1.0-1.1) 2.8 (2.7-2.8) 1.0 (1.0-1.1) 0.4 (0.4-0.4) 1.0 (0.9-1.1)
5 (most deprived) 8.7 (8.5-8.9) Reference 2.7 (2.6-2.8) Reference 0.4 (0.4-0.5) Reference
Ethnicity n of eczema 5 18,583 n of eczema 5 12,862 n of eczema 5 391
White 8.6 (8.4-8.7) Reference 3.2 (3.1-3.2) Reference 0.4 (0.4-0.5) Reference
Mixed 11.9 (11.2-12.8) 1.4 (1.3-1.5) 3.5 (3.2-3.9) 1.1 (1.0-1.2) 0.5 (0.3-1.0) 1.2 (0.6-2.3)
Black Caribbean 20.6 (18.0-23.6) 2.7 (2.4-3.1) 5.3 (4.3-6.4) 1.8 (1.4-2.2) 1.5 (0.6-3.9) 3.2 (1.2-8.7)
Black African 15.3 (14.1-16.6) 2.0 (1.8-2.2) 3.8 (3.4-4.3) 1.3 (1.1-1.4) 1.1 (0.6-1.8) 2.3 (1.3-4.1)
Black other 18.6 (16.0-21.7) 2.4 (2.1-2.8) 3.8 (3.0-4.9) 1.3 (1.0-1.6) 2.4 (1.2-4.7) 5.2 (2.5-10.5)
Indian 17.3 (16.0-18.6) 1.7 (1.3-2.3) 4.0 (3.6-4.4) 1.3 (1.1-1.4) 0.9 (0.5-1.5) 2.0 (1.2-3.4)
Bangladeshi 23.4 (20.6-26.5) 2.9 (2.6-3.3) 5.1 (4.1-6.2) 1.6 (1.3-2.0) 0.9 (0.3-2.9) 2.0 (0.6-6.1)
Pakistani 14.1 (13.0-15.3) 1.8 (1.6-1.9) 4.0 (3.5-4.4) 1.3 (1.1-1.4) 0.8 (0.4-1.4) 1.7 (0.9-3.0)
Chinese 24.4 (20.9-28.5) 2.8 (2.4-3.3) 4.2 (3.1-5.7) 1.3 (1.0-1.8) 0.7 (0.1-4.6) 1.5 (0.2-10.5)
Asian other 15.1 (13.7-16.7) 1.8 (1.6-2.0) 4.2 (3.6-4.8) 1.3 (1.1-1.5) 1.7 (0.9-3.1) 3.7 (2.0-6.8)
Other 9.9 (8.8-11.0) 1.2 (1.1-1.4) 3.4 (3.0-4.0) 1.1 (1.0-1.3) 0.7 (0.3-1.7) 1.5 (0.6-3.7)
*Rate per 100 person-years.
Model adjusted for sex, Index of Multiple Deprivation, and the number of annual consultations during the study follow-up period.
J ALLERGY CLIN IMMUNOL
VOLUME 141, NUMBER 5
LETTERS TO THE EDITOR 1929.e7
TABLE E5. Results in the overall child population regardless of the general practitioner registration date related to birth: Incidence rates
and rate ratios of eczema by sociodemographic factors stratified by age (N 5 1,472,337 for analysis on sex and Index of Multiple
Deprivation and N 5 392,830 for analysis on ethnicity)
Characteristic
<1-y-olds (n of eczema 5 59,840) 1-4-y-olds (n of eczema 5 44,111) 5-17-y-olds (n of eczema 5 22,527)
Rate* (95% CI) aRRy (95% CI) Rate* (95% CI) aRRy (95% CI) Rate* (95% CI) aRRy (95% CI)
Sex
Male 15.9 (15.7-16.1) 1.3 (1.3-1.4) 2.8 (2.8-2.9) 1.0 (1.0-1.0) 0.4 (0.4-0.4) 0.7 (0.7-0.7)
Female 11.7 (11.6-11.8) Reference 2.9 (2.8-2.9) Reference 0.5 (0.5-0.5) Reference
Index of Multiple Deprivation
1 (least deprived) 15.6 (15.4-15.9) 1.2 (1.2-1.3) 3.1 (3.1-3.2) 1.3 (1.2-1.3) 0.4 (0.4-0.4) 0.9 (0.9-1.0)
2 13.8 (13.5-14.0) 1.1 (1.0-1.1) 2.9 (2.8-2.9) 1.2 (1.1-1.2) 0.4 (0.4-0.4) 0.9 (0.9-0.9)
3 13.6 (13.3-13.8) 1.1 (1.0-1.1) 2.8 (2.7-2.9) 1.1 (1.1-1.2) 0.4 (0.4-0.5) 0.9 (0.9-1.0)
4 13.1 (12.9-13.3) 1.0 (1.0-1.1) 2.7 (2.7-2.8) 1.1 (1.1-1.1) 0.5 (0.5-0.5) 1.0 (1.0-1.0)
5 (most deprived) 12.9 (12.6-13.1) Reference 2.7 (2.6-2.7) Reference 0.5 (0.5-0.5) Reference
Ethnicity n of eczema 5 26,958 n of eczema 5 15,269 n of eczema 5 1,824
White 12.4 (12.2-12.5) Reference 3.1 (3.1-3.2) Reference 0.5 (0.5-0.5) Reference
Mixed 17.8 (16.8-18.8) 1.5 (1.4-1.6) 3.6 (3.3-3.9) 1.2 (1.1-1.4) 0.7 (0.5-0.9) 1.4 (1.0-1.9)
Black Caribbean 28.6 (25.5-32.0) 2.5 (2.3-2.8) 5.3 (4.4-6.4) 2.1 (1.7-2.5) 1.7 (1.1-2.5) 3.5 (2.4-5.2)
Black African 21.9 (20.6-23.4) 1.9 (1.8-2.1) 3.9 (3.5-4.3) 1.5 (1.3-1.6) 1.0 (0.8-1.2) 2.1 (1.7-2.6)
Black other 28.5 (25.2-32.2) 2.5 (2.2-2.8) 3.9 (3.2-4.9) 1.4 (1.1-1.8) 1.8 (1.3-2.5) 3.7 (2.6-5.3)
Indian 24.1 (22.7-25.6) 1.9 (1.7-2.0) 4.0 (3.7-4.4) 1.3 (1.2-1.4) 1.0 (0.9-1.3) 2.2 (1.8-2.7)
Bangladeshi 31.2 (28.0-34.8) 2.4 (2.1-2.9) 5.3 (4.4-6.3) 1.6 (1.3-1.9) 1.2 (0.7-2.1) 2.3 (1.3-4.0)
Pakistani 20.1 (18.7-21.5) 1.6 (1.5-1.8) 3.8 (3.5-4.2) 1.1 (0.9-1.3) 1.0 (0.8-1.2) 1.8 (1.5-2.3)
Chinese 41.8 (37.1-41.1) 3.4 (3.0-3.8) 4.6 (3.5-5.9) 1.7 (1.3-2.2) 0.5 (0.2-1.6) 1.1 (0.3-3.3)
Asian other 23.6 (21.8-25.5) 2.0 (1.8-2.1) 4.3 (3.8-4.9) 1.3 (1.2-1.5) 1.2 (0.8-1.6) 2.3 (1.6-3.2)
Other 16.7 (15.4-18.2) 1.3 (1.2-1.5) 3.2 (2.8-3.6) 1.1 (1.0-1.3) 0.9 (0.7-1.2) 1.9 (1.4-2.6)
*Rate per 100 person-years.
Model adjusted for sex, Index of Multiple Deprivation, and the number of annual consultations during the study follow-up period.
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